Rana McKay, MD, on radium-223 plus cabozantinib in renal cell carcinoma

In the following interview, conducted at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, Rana R. McKay, MD, FASCO, discussed findings from the phase 2 RadiCal trial (Alliance A031801, NCT04071223) evaluating the addition of radium-223 dichloride (Ra-223) to cabozantinib (Cabometyx) in patients with renal cell carcinoma and bone metastases. McKay is a genitourinary medical oncologist at the University of California, San Diego.